Lyell Immunopharma, Inc. — Net Income by Fiscal Year
7 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/a96a84fb-06ed-4a44-8009-4426a2a45b93/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-274.4M | 2025-01-01 – 2025-12-31 | evidence 0001628280-26-017253 |
| FY 2024 | $-343.0M | 2024-01-01 – 2024-12-31 | evidence 0001628280-25-011978 |
| FY 2023 | $-234.6M | 2023-01-01 – 2023-12-31 | evidence 0001628280-24-007592 |
| FY 2022 | $-183.1M | 2022-01-01 – 2022-12-31 | evidence 0001628280-23-005572 |
| FY 2021 | $-250.2M | 2021-01-01 – 2021-12-31 | evidence 0001628280-22-007708 |
| FY 2020 | $-204.5M | 2020-01-01 – 2020-12-31 | evidence 0001628280-22-007708 |
| FY 2019 | $-129.4M | 2019-01-01 – 2019-12-31 | evidence 0001628280-22-007708 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Lyell Immunopharma, Inc. — all facts · Revenue · Operating Income